You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)九個產品於全國藥品集中採購中擬中選
阿思達克 11-09 09:06
華潤醫藥(03320.HK)公布,旗下多家公司於11月6日參加國家組織藥品聯合採購辦公室的第九批全國藥品集中採購,旗下共有九個產品擬中選本次集中採購,涉及心腦血管、生殖系統、消化道、生殖系統、抗感染等多個治療和疾病領域。 是次中選產品包括華潤三九(雅安)藥業的鹽酸烏拉地爾注射液、華潤賽科藥業的奧美沙坦酯氫氯(口塞)口秦片及賽洛多辛膠囊、華潤雙鶴藥業的拉考沙胺口服溶液、華潤雙鶴利民藥業(濟南)的胞磷膽鹼鈉注射液及葡萄糖酸鈣注射液、晉城海斯製藥的雷貝拉唑鈉腸溶片、南京新百藥業縮宮素注射液,以及江西博雅欣和製藥的西他沙星片。 華潤醫藥預期,擬中選的部分藥品價格較擬中選省份現銷售價格有一定程度下降,但通過簽訂購銷合同將有利於提高相關產品的市場佔有率,以及提升集團製藥業務的品牌影響力。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account